Brain Metastases Clinical Trials 2023

What are the top hospitals conducting brain metastases research?

When it comes to pioneering clinical trials for patients with brain metastases, several prominent hospitals are leading the charge. In Houston, M D Anderson Cancer Center stands out with an impressive 13 ongoing trials focused specifically on this condition and a total of 43 completed studies since their first brain metastases trial in 2004. Not far behind, Moffitt Cancer Center in Tampa is making significant strides as well, currently conducting nine active trials and having recorded a commendable history of 22 previous brain metastases studies since their initial trial in 2004.

In Urbana, Carle Cancer Center is contributing to advancements in this field with six ongoing clinical trials for brain metastases and a notable record of 14 previously conducted studies dating back to their inaugural trial in 2003. Meanwhile, at Dana-Farber Cancer Institute located in Boston, researchers are working diligently on six active clinical investigations while boasting a remarkable tally of 31 completed brain metastases trials since initiating their first study back in 2002.

Moreover adding itself among these esteemed institutions is the Ohio State University Comprehensive Cancer Center based out of Columbus. Although relatively new compared to its counterparts, they have already made substantial contributions by carrying out six currently active brain metastases trials along with eleven previously held investigations; theirs can be traced back only ten years ago to2012.

These leading hospitals across different locations demonstrate the commitment and progress being made within the medical community towards understanding and treating brain metastases. Each trial serves as an opportunity to expand our knowledge and improve patient outcomes for those facing this challenging condition. With continued research efforts at these institutions and others like them around the world, we move closer towards finding effective treatments that may ultimately transform lives affected by brain metastases

Which are the best cities for brain metastases clinical trials?

When it comes to brain metastases clinical trials, several cities emerge as prominent hubs of research and innovation. Boston, Massachusetts leads the way with 29 ongoing trials focusing on treatments like PF-07284890, Dose Escalation Cohorts - Monotherapy, Stereotactic Radiation, among others. New York, New York closely follows with 23 active studies exploring options such as PF-07284890 and Pembrolizumab combined with SRS. Houston, Texas also showcases its dedication to advancing brain metastases treatment through its 23 active trials investigating approaches like Stereotactic Radiosurgery and NovoTTF-200M device for Glioblastoma Multiforme, Massachusetts leads the way with 29 ongoing trials focusing on treatments like PF-07284890, Dose Escalation Cohorts - Monotherapy, Stereotactic Radiation, among others. New York, New York closely follows with 23 active studies exploring options such as PF-07284890 and Pembrolizumab combined with SRS. Houston, Texas also showcases its dedication to advancing brain metastases treatment through its 23 active trials investigating approaches like Stereotactic Radiosurgery and NovoTTF-200M device for Glioblastoma Multiforme. While Tampa, Florida presents a range of clinical trials including Encorafenib and Phase 1b Substudy A Dose Expansion Cohort 2.

From coast to coast these cities provide patients dealing with brain metastases an opportunity to participate in cutting-edge clinical trials that could potentially revolutionize treatment options for this challenging condition.

Which are the top treatments for brain metastases being explored in clinical trials?

Clinical trials are paving the way for advanced treatments targeting brain metastases. Stereotactic radiosurgery, a precise radiation treatment technique, stands at the forefront with 10 ongoing trials and an impressive track record of 37 all-time clinical studies since its debut in 2004. Nivolumab, an immunotherapy7 all-time clinical studies since its debut in 2004. Nivolumab, an immunotherapy drug, follows closely behind with five active trials and a solid foundation of 19 previous brain metastases trials starting from 2014. Additionally, stereotactic radiation and osimertinib show promise in their respective fields as they undergo testing in two active trials each while accumulating three and eight total brain metastases trials respectively as of now. The relentless pursuit to improve outcomes for patients battling this challenging condition remains steadfast through these groundbreaking investigations.

What are the most recent clinical trials for brain metastases?

Recent clinical trials offer hope for patients with brain metastases, a challenging condition that arises when cancer cells spread to the brain from other parts of the body. One promising treatment being studied is cemiplimab, which is currently in Phase 2 and has shown potential in targeting brain metastases. Another trial explores the combination of azeliragon and stereotactic radiosurgery (SRS) as a possible treatment option for this complex condition. Additionally, a single-arm study aims to evaluate the efficacy of a specific treatment approach for brain metastases. These ongoing trials present opportunities to improve outcomes and enhance the quality of life for individuals facing this difficult diagnosis.

What brain metastases clinical trials were recently completed?

Recent clinical trials have made significant progress in the field of brain metastases, offering hope for patients facing this challenging condition. In October 2020, Blue Earth Diagnostics completed a trial investigating the potential of 18F fluciclovine. Not far behind, in August 2020, they concluded another trial with the same therapy. Emory University also achieved an important milestone by completing their WP1066 study in May 2020. These recent advancements signify the commitment of researchers to find effective treatments for brain metastases and bring us closer to improved outcomes for patients dealing with this complex disease.